Edition:
India

Hikma Pharmaceuticals PLC (HIK.L)

HIK.L on London Stock Exchange

934.80GBp
16 Feb 2018
Change (% chg)

33.80 (+3.75%)
Prev Close
901.00
Open
907.00
Day's High
934.80
Day's Low
897.80
Volume
406,605
Avg. Vol
970,521
52-wk High
2,346.00
52-wk Low
840.60

Select another date:

Tue, Dec 19 2017

Hikma wins right to market Roche drug copy in Middle East and North Africa

Hikma Pharmaceuticals Plc has won exclusive rights to distribute and market its third biosimilar drug - a copy of Roche's blood cancer treatment Rituxanin - in the Middle East and North African markets, it said on Tuesday.

Hikma wins right to market Roche drug copy in Middle East and North Africa

Dec 19 Hikma Pharmaceuticals Plc has won exclusive rights to distribute and market its third biosimilar drug - a copy of Roche's blood cancer treatment Rituxanin - in the Middle East and North African markets, it said on Tuesday.

BRIEF-Hikma Pharmaceuticals ‍Reaches Licensing Agreement With Celltrion

* ‍REACHES LICENSING AGREEMENT WITH CELLTRION FOR THIRD BIOSIMILAR PRODUCT IN MIDDLE EAST AND NORTH AFRICA​

BRIEF-Hikma Says Hikma Ventures Has Participated In Financing For Prognos​

* ‍VENTURE CAPITAL ARM, HIKMA VENTURES HAS PARTICIPATED IN A $20.5 MILLION SERIES C ROUND OF FINANCING FOR PROGNOS​ Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 80 6749 1136)

BRIEF-Hikma Pharmaceuticals ‍invests in biosensor tech firm Biolinq​

* HIKMA PHARMACEUTICALS PLC - ‍INVESTED IN BIOLINQ IN COLLABORATION WITH M VENTURES WHICH LED $10 MILLION SERIES A ROUND OF FINANCING​ Source text for Eikon: Further company coverage:

BRIEF-Hikma Pharmaceuticals acquires six products from Boehringer Ingelheim GmbH

* ‍HIKMA ACQUIRES PRODUCTS IN EUROPE FROM BOEHRINGER INGELHEIM​

Drugmaker Hikma cuts generics sales forecast a third time

Nov 9 Hikma Pharmaceuticals Plc on Thursday lowered 2017 revenue guidance for its generics business for a third time.

BRIEF-Hikma Pharmaceuticals says ‍continue to expect FY revenue around $2.0 bln​

* ‍CONTINUE TO EXPECT FULL YEAR REVENUE TO BE AROUND $2.0 BILLION IN CONSTANT CURRENCY IN 2017​

BRIEF-Hikma launches serious infections treatment in the United States

* ‍CAPSULES ARE INDICATED FOR TREATMENT OF SERIOUS INFECTIONS CAUSED BY SUSCEPTIBLE STRAINS OF CANDIDA AND/OR CRYPTOCOCCUS​ Source text for Eikon: Further company coverage:

BRIEF-Hikma says US unit launched pantoprazole sodium for injection

* U.S. unit west-ward pharmaceuticals has launched pantoprazole sodium for injection, 40mg​ Source text for Eikon: Further company coverage:

Select another date: